Insider buying last 90 days
No open-market insider purchases were filed for AMRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AMRX insider filing, plotted on the chart in Gekko.Open AMRX in Gekko
NASDAQ: AMRX
Amneal Pharmaceuticals (AMRX) Stock Analysis & Forecast
Sep 28 close
$20.50+0.73 (+3.7%)
Gekko Brief
AI summaryAmneal shares rose 3.7% to $20.50 this week, touching a fresh 52-week high along the way, with recent coverage framing the move in the context of its strong year-over-year performance. Alongside the price action, several Form 4 filings were reported, including a transfer by director J. Kevin Buchi of 20,445 shares of Class A stock to a trust he oversees, made without consideration.
The stock trades above both its 50-day average of $18.13 and its 200-day average of $14.85, with the shorter-term average sitting above the longer-term one, consistent with an established uptrend. The GekkoIndex reading of 45 places the stock in the Neutral zone. Against this backdrop, the price of $20.50 sits 14.3% above the Gekko Fair Value of $17.93.
Over the next 20 trading days, the next earnings report is scheduled for 29 October, which falls outside that window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, this point in the calendar has produced an average 20-day return of -0.1% over five years, with gains in three of those years. Consensus among 7 covering firms stands at a buy rating with a target of $22.71.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Amneal Pharmaceuticals price vs fair value
Close $20.50200-day averageGekko Fair Value $17.93
Amneal Pharmaceuticals quick facts
- Market cap
- $6.55B
- P/E ratio
- 41.2
- Forward P/E
- 6.3
- EPS, TTM
- $0.48
- Revenue, TTM
- $3.12B
- Profit margin
- 5.1%
- Dividend yield
- —
- Beta
- 1.24
- Volume
- 2.77M avg 2.58M
- 1-year return
- +113.5%
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±8.2%
- 50-day average
- $18.13
- 200-day average
- $14.85
- Next earnings
- Oct 29 before open
- Shares outstanding
- 348.3M
Amneal Pharmaceuticals swing-trade checklist
Amneal Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $20.50 is above the 50-day ($18.13) and 200-day ($14.85) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
45, Neutral
Reading 45 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
14.3% above
Price is 14.3% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Oct 29, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−0.1% on average
From this point in the calendar, the next 20 trading days averaged −0.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Amneal Pharmaceuticals stock chart and price history
Amneal Pharmaceuticals closed at $20.50 on Sep 28, 2026, +113.5% over the past year, inside a 52-week range of $9.56 to $21.18.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +13.8%
- 3 months
- +18.6%
- 6 months
- +73.0%
- 1 year
- +113.5%
The full AMRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AMRX in Gekko
Follow Amneal Pharmaceuticals through every session
Put AMRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AMRX in GekkoFree for 7 days. No credit card required.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals develops, licenses, manufactures, markets and distributes both generic and branded medicines across many delivery forms, addressing a wide range of treatment needs. It works with dosage types such as tablets, injectables, eye drops, liquids, topical treatments, softgels, inhalants and patches, and its branded lineup includes Emverm for parasitic infections, Rytary for Parkinson's disease, and Unithroid for hypothyroidism.
The business runs through three segments. Generics covers the creation and sale of complex drug formulations. Specialty focuses on developing and marketing proprietary branded medicines, with emphasis on neurological, endocrine and parasitic conditions. AvKARE supplies pharmaceuticals and medical and surgical goods to government bodies, notably the Department of Defense and the Department of Veterans Affairs, and also handles bulk packaging and distribution of medicines and supplements under the AvKARE and AvPAK names for retail and institutional buyers. Products move through wholesalers, distributors, hospitals, pharmacy chains and independent drugstores, with activity spanning the United States, India, Ireland and other markets.
Amneal traces back to 2002, when it was set up as Atlas Holdings, Inc., taking its current name in 2018. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ under the ticker AMRX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- amneal.com
Amneal Pharmaceuticals GekkoIndex: the smart money zone
Amneal Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45, in the Neutral zone, up 2.7 points over five sessions.
45Neutral
Up 2.7 points over five sessions, from the Distribution zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 12 | +0.6% | +6.2% | ||
| Accumulation | 152 | +2.6% | +8.0% | ||
| Neutral (current zone) | 443 | +0.7% | +3.0% | ||
| Distribution | 63 | +0.4% | +2.5% | ||
| Selling | 2 | Too few readings yet | |||
Average AMRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the AMRX price, zone by zone.Track AMRX in Gekko
Is Amneal Pharmaceuticals stock overvalued? Gekko Fair Value
Amneal Pharmaceuticals trades 14.3% above Gekko Fair Value of $17.93, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Amneal Pharmaceuticals shares are worth, recalculated every trading day.
$17.93
Gekko Fair Value, Sep 29, 2026
14.3% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AMRX in Gekko
Amneal Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Amneal Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AMRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AMRX, plotted on the chart in Gekko.Open AMRX in Gekko
Buybacks
Amneal Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2024
- $194K
- As a share of market cap
- 0.00%
From company filings.
Amneal Pharmaceuticals earnings: next date and track record
Amneal Pharmaceuticals reports on Oct 29, 2026, before the open (30 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 30 days away
- EPS estimate
- $0.23
- Revenue estimate
- $812.3M
7 of 8reports beat the EPS estimate
±3.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Amneal reported strong Q2 2026 results, with revenue of $796M (up 10%), adjusted EBITDA of $206M (up 12%), and adjusted EPS of $0.30 (up 20%). Management described the company as being in a transformative period driven by diversification across Affordable Medicines, Specialty brands, biosimilars (pending Kashiv acquisition), GLP-1s and complex generics including transdermals and injectables. They raised the 2026 outlook for the second time this year and highlighted continued momentum into 2027. Key growth drivers include increased demand for women's health transdermal patches (capacity being expanded), new product launches (added $45M in Q2), strong Specialty brand performance (CREXONT, UNITHROID, BREKIYA), expansion of biosimilars capability via Kashiv, and complex product launches such as lanreotide and iohexol. Management emphasized manufacturing upgrades (digitization, automation, AI), operational resiliency, and planned capacity expansion. During Q&A, management reiterated conservative inclusion of lanreotide in guidance (some revenue included) while XOLAIR is expected late in the year or into early next year (not included). They quantified iohexol as a potential $50M+ opportunity and suggested Affordable Medicines could add $1–$2 billion of revenue by 2030. They described the Kashiv acquisition as enabling 6 commercial biosimilars by next year and reiterated focus on integrating Kashiv and advancing biosimilar filings.
- Guidance
- Company raised its 2026 outlook (no detailed numeric guidance disclosed on the call). Management indicated they conservatively included some lanreotide contribution in 2H guidance but did not include XOLAIR for this year. They expect continued momentum through 2026 into 2027. Management expects iohexol to meaningfully contribute in 2027 and estimated Affordable Medicines could add $1–$2 billion by 2030. Kashiv integration is expected to yield 6 commercial biosimilars (ALYMSYS, RELEUKO, FYLNETRA, Prolia, XGEVA, XOLAIR) commercialized by next year; they aim to file 3–4 biosimilars per year going forward.
- Risks flagged
- Operational risk from localized flooding at Gujarat manufacturing site (limited impact expected; operations to resume in weeks). Regulatory/timing risk for product approvals (lanreotide, XOLAIR) — management is optimistic but conservative in modeling. Market/policy risk from potential tariffs announced by administration (company awaiting details and will collaborate). Segment-specific headwinds: AvKARE revenue down 4% due to distribution mix and low-margin business. Supply chain and manufacturing complexity for products like lanreotide and iohexol create execution risk. Competitive risk/timing for biosimilar launches and potential spillover of approvals into next fiscal period.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.27 est $0.24 | $796.2M est $768.2M | −4.1% |
| May 7, 2026 | $0.27 est $0.19 | $722.5M est $719.7M | −3.1% |
| Feb 27, 2026 | $0.21 est $0.18 | $814.3M est $807.4M | −5.0% |
| Oct 30, 2025 | $0.17 est $0.13 | $784.5M est $806.1M | +3.7% |
| Aug 5, 2025 | $0.25 est $0.18 | $724.5M est $768.6M | +1.1% |
| May 2, 2025 | $0.21 est $0.15 | $695.4M est $744.2M | −2.6% |
| Feb 28, 2025 | $0.12 est $0.15 | $730.5M est $723.1M | +4.5% |
| Nov 8, 2024 | $0.16 est $0.13 | $702.5M est $700.8M | +6.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Amneal Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Amneal Pharmaceuticals is $22.71, +10.8% from the last close, from 7 firms rating the stock in the last 90 days.
$22.71consensus 12-month target, +10.8% from the last close
Now $20.50Avg $22.71
Low $17High $27
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Oppenheimer | $27 | +31.7% |
| Sep 21 | J.P. Morgan | — | — |
| Sep 21 | Barclays | $20 | −2.4% |
| Sep 17 | Leerink Partners | $23 | +12.2% |
| Sep 16 | Barclays | $20 | −2.4% |
+3.0%average 20-day move after past Neutral readings
−0.1%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Amneal Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Amneal Pharmaceuticals averaged −0.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.2% | 3 of 5 |
| Next 10 trading days | −1.3% | 2 of 5 |
| Next 15 trading days | −0.4% | 4 of 5 |
| Next 20 trading days | −0.1% | 3 of 5 |
| Next 30 trading days | +6.5% | 3 of 5 |
For scale, AMRX’s typical 20-trading-day move in either direction is about 8.2%.
Amneal Pharmaceuticals market cap and key statistics
Amneal Pharmaceuticals’s market cap is $6.55B, with a P/E ratio of 41.2 and revenue of $3.12B over the last twelve months.
Valuation
- Market cap
- $6.55B
- P/E ratio
- 41.2
- Forward P/E
- 6.3
- EPS, TTM
- $0.48
- Gekko Fair Value
- $17.93
Trading
- Volume
- 2.77M
- Avg volume, 20 days
- 2.58M
- 52-week high
- $21.18
- 52-week low
- $9.56
- Shares outstanding
- 348.3M
Financials
- Revenue, TTM
- $3.12B
- Profit margin
- 5.1%
- Return on equity
- 61.3%
- Quarterly earnings growth, YoY
- +157.1%
Risk and income
- Beta
- 1.24
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±8.2%
Amneal Pharmaceuticals stock news this week
Coverage of Amneal Pharmaceuticals this week reads neutral: 1 positive, 5 neutral and 0 negative headlines.
- A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50GuruFocus, Sep 28
- Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.comInvesting.com Canada, Sep 23
- Form 4 Amneal Pharmaceuticals Inc Class A For: 23 SeptemberInvesting.com India, Sep 23
- Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.comInvesting.com Nigeria, Sep 22
- Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he overseesStock Titan, Sep 22
- Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to TrustKalkine Media, Sep 22
Amneal Pharmaceuticals peers
Amneal Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Amneal Pharmaceuticals stock FAQ
What is Amneal Pharmaceuticals’s market cap?
Amneal Pharmaceuticals’s market cap is $6.55B at the Sep 28, 2026 close of $20.50, with 348.3M shares outstanding. The shares trade on a P/E ratio of 41.2.
What is the Amneal Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Amneal Pharmaceuticals is $22.71, +10.8% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Amneal Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Amneal Pharmaceuticals is overvalued: the Sep 28, 2026 close of $20.50 is 14.3% above Gekko Fair Value of $17.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Amneal Pharmaceuticals report earnings next?
Amneal Pharmaceuticals is expected to report on Oct 29, 2026, before the market opens (30 days away). Analysts expect earnings of $0.23 per share on revenue of $812.3M. Amneal Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 3.9% on average across the report.
What is Amneal Pharmaceuticals’s 52-week high and low?
Amneal Pharmaceuticals’s 52-week high is $21.18 and its 52-week low is $9.56; it closed at $20.50 on Sep 28, 2026, +113.5% over the past year.
Is Amneal Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Amneal Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.